Suppr超能文献

[志贺氏菌对某些化疗制剂的体外耐药性及交叉耐药性的发展]

[Development of drug resistance and the cross resistance in Shigella to certain chemotherapeutic preparations in vitro].

作者信息

Chernomordik A B, Bass T M, Ozerianskaia N M, Mukhorskaia V A, Rzhanova V I

出版信息

Antibiotiki. 1976 Sep;21(9):808-12.

PMID:136923
Abstract

A total of 700 Shigella cultures isolated in different regions of the Ukraine in 1974 and occasionally in 1971-1973 were studied. No cultures resistant to furazolidone or enteroseptol were found. Under the experimental conditions resistance to nitrofuran and especially oxycholine preparations in Shigella developed slowly when the cultures were passaged in broths with increasing concentrations of the drugs. Cross resistance in Shigella was observed with respect to (a) various nitrofuran preparations, less pronounced with respect to furacryline and (b) enteroseptol and 5-NOK. No cross resistance was noted between the above groups of the chemotherapeutics and levomycetin and tetracycline. 5-NOK inhibited the resistance development to streptomycin, while enteroseptol inhibited the development of resistance to furazolidone in Shigella. The studies showed that in the near future there will be observed no mass development of resistance to furazolidone and enteroseptol in Shigella.

摘要

对1974年在乌克兰不同地区分离出的700株志贺氏菌培养物进行了研究,1971 - 1973年偶尔也有分离。未发现对呋喃唑酮或肠炎磺有抗性的培养物。在实验条件下,当培养物在含有浓度不断增加的药物的肉汤中传代时,志贺氏菌对硝基呋喃尤其是对羟基胆碱制剂的抗性发展缓慢。志贺氏菌存在交叉抗性,涉及:(a) 各种硝基呋喃制剂,对呋丙烯的交叉抗性较弱;(b) 肠炎磺和5-硝基糠醛缩氨基脲。上述化疗药物组与氯霉素和四环素之间未发现交叉抗性。5-硝基糠醛缩氨基脲抑制了志贺氏菌对链霉素抗性的发展,而肠炎磺抑制了志贺氏菌对呋喃唑酮抗性的发展。研究表明,在不久的将来,志贺氏菌对呋喃唑酮和肠炎磺不会出现大规模的抗性发展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验